Transcriptome investigation of anti‐inflammation and immuno‐regulation mechanism of taurochenodeoxycholic acid

Table 3 RNA-seq data quality analysis results

Sample name	Raw data		Valid data		Efficient(reads)%	Q20 %	Q30 %	GC content%
Sample name	Read	Base	Read	Base	Efficient(reads)%	Q20 %	Q30 %	GC content%
FCA1	54,383,990	8.16G	53,835,634	8.08G	98.99	99.58	95.01	51.50
FCA2	41,050,214	6.16G	40,649,424	6.10G	99.02	99.77	96.14	52.00
FCA3	40,700,236	6.11G	40,326,736	6.05G	99.08	99.76	95.82	51.50
AT10_1	40,741,106	6.11G	40,307,186	6.05G	98.93	99.60	95.16	51.00
AT10_2	57,742,958	8.66G	57,142,398	8.57G	98.96	99.42	92.66	50.50
AT10_3	51,520,986	7.73G	50,998,720	7.65G	98.99	99.62	93.96	50.50
AT1_1	54,593,420	8.19G	54,067,912	8.11G	99.04	99.60	93.56	51.00
AT1_2	46,452,368	6.97G	46,050,198	6.91G	99.13	99.63	93.87	51.50
AT1_3	50,198,580	7.53G	49,764,940	7.46G	99.14	99.32	91.97	51.00
AT01_1	56,340,820	8.45G	55,884,918	8.38G	99.19	99.38	92.94	52.50
AT01_2	52,741,640	7.91G	52,255,040	7.84G	99.08	99.58	94.17	51.50
AT01_3	85,115,910	12.77G	84,203,182	12.63G	98.93	99.58	94.00	50.50

In the experimental design, the AA rat FLS group was represented as FCA groups in the Table 1; AA rat FLS + TCDCA high dose treatment was represented as AT10 group; AA rat FLS + TCDCA medium dose treatment was represented as AT1 group; AA rat FLS + TCDCA low dose treatment was represented as AT01 group; The numbers 1, 2, and 3 represented three sets of repeated studies

ISSN: 2050-6511